Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
We have evaluated the safety and immunogenicity of a recombinant modified vaccinia virus Ankara (MVA) vector expressing the respiratory syncytial virus (RSV) fusion (F) and attachment (G) proteins in infant macaques. Animals were vaccinated twice and 4 months later challenged with RSV. Although vaccination did not predispose for immunopathology upon challenge, we were also unable to demonstrate protection. Since vaccination had resulted in priming for secondary immune responses upon challenge, we suggest that vaccination efficacy will have to be improved by using MVA in a prime-boost strategy.
de Waal
Leon
L
Department of Virology, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands.
Wyatt
Linda S
LS
Yüksel
Selma
S
van Amerongen
Geert
G
Moss
Bernard
B
Niesters
Hubert G M
HG
Osterhaus
Albert D M E
AD
de Swart
Rik L
RL
D000818:Animals; D008252:Macaca fascicularis; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D014614:Vaccines, Synthetic; D014765:Viral Vaccines